.jpg "Aclaris Therapeutics Inc (NASDAQ: ACRS)")
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aclaris Therapeutics Inc (NASDAQ: ACRS) and Global Blood Therapeutics (NASDAQ: GBT) with bullish sentiments.
Aclaris Therapeutics Inc (NASDAQ: ACRS)
In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Aclaris Therapeutics Inc (NASDAQ: ACRS), with a price target of $50. The company’s shares closed yesterday at $19.78.
Chen observed:
“We rate ACRS as 12-month price target of $50. We expect upwards earnings revisions to levels not reflected in sell-side consensus expectations to drive shares higher. This could come from positive news flow for each of Aclaris’ three key programs over the next 12-18 months. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12- month price target of $50.”
According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of -4.1% and a 42.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Paratek Pharmaceuticals, Spero Therapeutics Inc, and Revance Therapeutics.
Aclaris Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $50.
See today’s analyst top recommended stocks >>
Global Blood Therapeutics (NASDAQ: GBT)
William Blair analyst Raju Prasad maintained a Buy rating on Global Blood Therapeutics (NASDAQ: GBT) today. The company’s shares closed yesterday at $47.05.
Prasad said:
“We note that this data is in line with the 5 of 12 (42%) evaluable patients at the abstract cutoff of January 2018. Furthermore, the median increase in hemoglobin was 0.7 g/dL, which we continue to view as an impressive result given that 88% of patients are concomitantly using hydroxyurea and the study has a baseline of 8.9 g/dL.”
According to TipRanks.com, Prasad is a 4-star analyst with an average return of 32.4% and a 72.7% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Audentes Therapeutics, Spark Therapeutics, and PTC Therapeutics.
Currently, the analyst consensus on Global Blood Therapeutics is Strong Buy and the average price target is $72.13, representing a 53.3% upside.
In a report released today, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $69 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
